Contact Us | Site Map | SEARCH
 
About HDNAbout RhophylacThe Rhophylac PromiseHigh PurityRapid PerformanceProven EddicacyEnhanced SafetyAdded ConvenienceProfessional ResourcesOrdering and ReimbursementPatient EducationRequest More InformationImportant Safety InformationPrescribing Information
Rhophylac has you covered

The Rhophylac® Promise™ of enhanced safety

Lowell Tilzer, MD speaks about Rhophylac® and Safety

More than 2 million doses administered worldwide, with no confirmed cases of viral transmissions1

Safety in plasma collection

  • Plasma collected from US donors only at company-operated and FDA-licensed collection facilites
  • Plasma-tested for HBsAg, HIV-1/2, and HCV antibodies
  • NAT testing, using the PCR method to confirm the absence of HIV, HAV, HCV, and parvovirus B19
Rhophylac® Assurance of Safety

Safety through state-of-the-art manufacturing

The unique and patented ChromaPlus™ manufacturing process utilizes 3 complementary viral safety steps for enhanced product safety

  1. Solvent detergent, which inactivates enveloped viruses (eg, HBV, HCV, HIV, and WNV)
  2. Ion-exchange chromatography, an advanced method of isolating RhIgG which also ensures that viruses that are potentially present are further depleted
  3. Nanofiltration with a 15 nm Planova® filter, which eliminates both enveloped and non-enveloped viruses (eg, parvovirus B19)
Rhophylac® Safety through manufacturing

HBsAg = HBV surface antigen
HIV-1/2 = human immunodeficiency virus
HCV = hepatitis C virus
NAT = nucleic acid testing
HAV = hepatitis A virus
HBV = hepatitis B virus
WNV = West Nile virus



References:
1. Data on file, CSL Behring LLC; 2008.


Important Safety Information

Rhophylac® is indicated for suppression of rhesus (Rh) isoimmunization in:

  • Pregnancy and obstetric conditions in non-sensitized, Rho(D)-negative women with an Rh-incompatible pregnancy, including routine antepartum and postpartum Rh prophylaxis and Rh prophylaxis in cases of obstetric complications, invasive procedures during pregnancy, or obstetric manipulative procedures.
  • Incompatible transfusions in Rho(D)-negative individuals transfused with blood components containing Rho(D)-positive red blood cells.

For suppression of Rh isoimmunization, Rhophylac® can be administered IM or IV.

Rhophylac® is indicated to raise platelet counts in Rho(D)-positive, non-splenectomized adult patients with chronic immune thrombocytopenic purpura (ITP). For the treatment of ITP, Rhophylac® must be administered IV.

Rhophylac® is contraindicated in individuals with known anaphylactic or severe systemic reaction to human immune globulin products.

Allergic or hypersensitivity reactions may occur with Rhophylac®; early signs of hypersensitivity include generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis. Individuals with selective IgA deficiency can develop antibodies to IgA and may develop severe hypersensitivity and anaphylactic reactions. For these individuals, weigh the expected benefits of treatment against the potential risks.

Rhophylac® is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Suppression of Rh Isoimmunization: For postpartum use following an Rh-incompatible pregnancy, Rhophylac® should not be given to the newborn infant.

The most common adverse reactions in the suppression of Rh isoimmunization with Rhophylac® are nausea, dizziness, headache, injection-site pain, and malaise.

Immune Thrombocytopenic Purpura: The most serious adverse reactions in patients receiving Rho(D) immune globulin have been observed in the treatment of ITP. ITP patients being treated with Rhophylac® should be monitored for signs and symptoms of intravascular hemolysis, including back pain, shaking chills, fever, and hemoglobinuria. Potentially serious complications of intravascular hemolysis include clinically compromising anemia, acute renal insufficiency, and, very rarely, disseminated intravascular coagulation, and death.

The most common adverse reactions observed in the treatment of ITP are chills, pyrexia/increased body temperature, and headache. Mild extravascular hemolysis has also been observed. In patients with preexisting anemia, weigh the benefits of Rhophylac® against the potential risk of increasing the severity of the anemia.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.